Delivery Order SPE2DB20D9331-SPE2DB25FL2A7
- Not listed
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc. on September 22, 2025, for the supply of Perjeta 420 mg/14 mL vials totaling $27,343.62 with firm fixed pricing. This delivery order was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA valued at $499,999,999 and effective through November 2026. The award carries no set-aside designation and requires completion by October 14, 2025, with performance based in Park Ridge,...
- The Defense Logistics Agency (DLA), operating under the Medical Supply Chain, awarded a delivery order valued at $91,145.20 to DMS Pharmaceutical Group Inc. on September 16, 2025, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order is scheduled for completion by October 7, 2025, with performance taking place at the contractor's location in Park Ridge, Illinois. The award was made without a set-aside designation, allowing DMS Pharmaceutical Group to compete directly...
- The Defense Logistics Agency awarded a delivery order valued at $9,114.54 to DMS Pharmaceutical Group Inc. for Perjeta 420 mg/14 ml vials on August 14, 2025, with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order represents a pharmaceutical supply requirement with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, is the prime contractor on this award. The delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $63,801.78 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, awarded on August 7, 2025, with an ultimate completion date of August 28, 2025, represents a specific supply requirement fulfilled under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA. The...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The contract, valued at $9,114.54 with a firm fixed-price structure, was awarded on September 23, 2025, with an ultimate completion date of October 15, 2025. This delivery order was issued without a set-aside designation, leveraging the vendor's competitive standing as a...
- The Defense Logistics Agency awarded a delivery order valued at $91,145.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a targeted pharmaceutical procurement to support Department of Defense healthcare operations. The award carries no set-aside...
- The Defense Logistics Agency awarded a $31,900.82 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 420 mg/14 mL vials of Perjeta, an oncology treatment medication. The award was issued on September 8, 2025, with an ultimate completion date of September 29, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing single-award...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,229.08 to DMS Pharmaceutical Group Inc. for the supply of Perjeta (pertuzumab) 420 mg/14 mL vials. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its Park Ridge facility with an ultimate completion date of October 10, 2025. The award was issued on September 19, 2025, without a set-aside designation, allowing...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth up to $25,529.76 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 4563969889 - Perjeta 420 mg/14 ml vial, 14 ml, with a performance period through April 1, 2024. This delivery order is issued under DMS Pharmaceutical Group's indefinite delivery contract SPE2DB24FSW68 with DLA, which has a ceiling value of up to...
- The Defense Logistics Agency awarded a $27,343.62 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The contract, issued on May 6, 2025, with an ultimate completion date of May 28, 2025, represents a focused procurement action without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract...
- SPE2DB20D9331Indefinite Delivery Contract
- SPE2DB20D9331-SPE2DB25FL2A7Delivery Order
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $54,687.24 to DMS Pharmaceutical Group Inc. on September 16, 2025, for the supply of Perjeta 420 mg/14 ml vials. This delivery order is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. The ultimate completion date for this delivery is October 7, 2025, and performance will be fulfilled from the contractor's location in Park Ridge, Illinois. No set-aside designation was used for this award. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler that serves as a critical supplier in the federal pharmaceutical supply chain, with a robust portfolio of delivery orders to military and federal healthcare facilities nationwide. The company specializes in distributing branded and generic prescription drugs, biologics, and medical consumables, including oncology treatments and specialty medications such as the Perjeta being procured under this order. This award exemplifies DMS Pharmaceutical Group's ongoing role in supporting Department of Defense healthcare operations through direct distribution of pharmaceutical products to military health facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $54.7k | 9/16/25 |